毒性结节性甲状腺肿与甲状腺癌:甲亢是否具有保护作用?
该回顾性研究比较了因孤立毒性结节或非毒性结节行甲状腺全切的患者,发现毒性结节性甲状腺肿组甲状腺癌发生率为19%,低于非毒性结节组的36.1%(P=.008),提示甲状腺癌在毒性结节性甲状腺肿中并不罕见。
要点
- 毒性结节性甲状腺肿术后甲状腺癌发生率为19%,并非既往认为的罕见。
- 毒性结节组甲状腺癌发生率低于非毒性孤立结节组(19% vs 36.1%,P=.008)。
- 应仔细病理检查高功能结节及结节外甲状腺组织以发现意外癌灶。
核心结论
- 因毒性结节性甲状腺肿手术的患者中甲状腺癌发生率为19%,并不像既往认为的那样罕见。
- 对高功能结节和结节外甲状腺组织均行仔细病理检查,可能有助于发现意外肿瘤灶。
研究设计与样本
- 回顾性研究,纳入因孤立毒性结节或非毒性结节行甲状腺全切的患者。
- 毒性结节性甲状腺肿组73例,非毒性孤立结节组366例。
主要发现
- 毒性结节性甲状腺肿组甲状腺癌14例(19%),非毒性孤立结节组132例(36.1%),P=.008。
- 毒性结节组中位年龄50岁(范围18-73),非毒性结节组42岁(范围18-83),P<.001。
- 毒性结节组中位结节直径40.9 mm(范围11.0-98.0),非毒性结节组23.3 mm(范围4.9-99.0),P<.001。
- 毒性结节组中位肿瘤直径6 mm(范围1-50),非毒性结节组14 mm(范围1-80),P=.150。
- 毒性结节组7例恶性结节为高功能结节本身(4例滤泡癌、3例甲状腺乳头状癌),另7例恶性灶位于受抑制的对侧叶且均为乳头状微小癌。
关键数值与推荐
- 甲状腺癌发生率:毒性结节性甲状腺肿组19%(14例),非毒性孤立结节组36.1%(132例),P=.008。
- 中位年龄:毒性结节组50岁(范围18-73),非毒性结节组42岁(范围18-83),P<.001。
- 中位结节直径:毒性结节组40.9 mm(范围11.0-98.0),非毒性结节组23.3 mm(范围4.9-99.0),P<.001。
- 中位肿瘤直径:毒性结节组6 mm(范围1-50),非毒性结节组14 mm(范围1-80),P=.150。
临床怎么用
- 对毒性结节性甲状腺肿行甲状腺切除时,不应因甲亢而低估甲状腺癌风险。
- 术后病理应同时关注高功能结节及结节外甲状腺组织,以发现意外癌灶。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The suppressive effect of the increase in thyroid hormone in patients with toxic nodular goiter is thought to protect the extranodular thyroid tissue from thyroid malignancy. In this study, we aimed to evaluate the prevalence and features of thyroid cancer in patients with toxic nodular goiter who underwent thyroidectomy. METHODS: Medical data of patients who had solitary toxic or nontoxic nodules and underwent total thyroidectomy were reviewed retrospectively. We reviewed the clinical, laboratory, and histopathologic features of patients with toxic nodular goiter and nontoxic solitary nodules. RESULTS: There were 73 patients with toxic nodular goiter and 366 patients with nontoxic solitary nodules. Median age was greater in the toxic nodular goiter compared with nontoxic solitary nodules patients (50 years; range: 18-73 vs 42 years; range: 18-83, P < .001). Median nodule diameters were 40.9 mm (range: 11.0-98.0) and 23.3 mm (range: 4.9-99.0) in patients with toxic nodular goiter and nontoxic solitary nodules, respectively (P < .001). Histopathologic examination revealed thyroid cancer in 14 patients (19%) with toxic nodular goiter and 132 (36.1%) patients with nontoxic solitary nodules (P = .008). Median tumor diameters were 6 mm (range: 1-50) in toxic nodular goiter and 14 mm (range: 1-80) in nontoxic solitary nodules (P = .150). The malignant nodule was the hyperfunctioning nodule in 7 patients with toxic nodular goiter; 4 were follicular and 3 were papillary thyroid cancer. The other 7 malignant foci were located in the suppressed contralateral lobe, and all were papillary microcarcinomas. The incidence of thyroid cancer outside the main nodule was similar in 2 groups (P = .934). CONCLUSION: Thyroid cancer in patients operated for toxic nodular goiter was 19%, which is not as rare as previously thought. A careful histopathologic examination of both the hyperfunctioning nodule and the extranodular thyroid tissue might help to disclose an unexpected tumor foci when thyroidectomy is performed in patients with toxic nodular goiter.
引用
- Tam AA, Ozdemir D, Alkan A, et al. Toxic nodular goiter and thyroid cancer: Is hyperthyroidism protective against thyroid cancer? Surgery. 2019. PMID: 31104806. doi:10.1016/j.surg.2019.03.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。